Carcinoid, Gastrointestinal, Neuroendocrine, Pancreatic
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
Due to completion of accrual to the first stage, accrual to EA2161 is temporarily suspended effective 11/5/18. Only patients who have signed a consent to participate on or before 3:00 PM MST November 5, 2018 will be accepted. Consented patients must be registered on or before 3:00 PM MST November 12, 2018.